Prostate Cancer, Advanced Or Metastatic: References

Content provided by Healthwise

References

Citations

1. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361(9360): 859–864.

2. American Cancer Society (2007). Cancer Facts and Figures 2007, pp. 1–52. Atlanta: American Cancer Society. Available online: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf.

3. Frankel S, et al. (2003). Screening for prostate cancer. Lancet, 361(9363): 1122–1128.

4. National Cancer Institute (2007). Prostate Cancer (PDQ): Prevention—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/prevention/prostate/HealthProfessional.

5. Robbins C, et al. (2007). Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Research, 17(12): 1717–1722.

6. National Cancer Institute (2007): Prostate Cancer (PDQ): Treatment—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/treatment/prostate/healthprofessional.

7. Calle EE, et al. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine, 348(17): 1625–1638.

8. Rodriguez C, et al. (2001). Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiology, Biomarkers and Prevention, 10(4): 345–353.

9. Brada M, et al. (2007). Proton therapy in clinical practice: Current clinical evidence. Journal of Clinical Oncology, 25(8): 965–970.

10. D'Amico AV, et al. (2007). Radiation therapy for prostate cancer. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 3006–3031. Philadelphia: Saunders Elsevier.

11. Berthold DR, et al. (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. Journal of Clinical Oncology, 26(2): 242–245.

12. Tunn U (2007). The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: Putting IAD under the spotlight. British Journal of Urology International, 99(Suppl 1): 19–24.

13. McNeel DG, Malkovsky M (2005). Immune-based therapies for prostate cancer. Immunology Letters, 96(1): 3-9.

14. Bader P, et al. (2003). Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? Journal of Urology, 169(3): 849–854.

15. Yuen KK, et al. (2006). Bisphosphonates for advanced prostate cancer. Cochrane Database of Systemic Reviews (4). Oxford: Update Software.

16. Foley KM (2005). Management of cancer pain. In VT DeVita Jr et al., eds., Cancer: Principles and Practice of Oncology, 7th ed., pp. 2615–2649. Philadelphia: Lippincott Williams and Wilkins.

17. Brigitte L, et al. (2004). Nonhormonal alternatives for the treatment of hot flashes. Pharmacotherapy, 24(1): 79–93.

18. Shahinian VB, et al. (2005). Risk of fracture after androgen deprivation for prostate cancer. New England Journal of Medicine, 352(2): 154–164.

19. Hellerstedt BA, Pienta KJ (2002). The current state of hormonal therapy for prostate cancer. CA—A Cancer Journal for Clinicians, 52(3): 154–179.

Other Works Consulted

• Kantoff PW (2007). Prostate cancer. In DC Dale, DD Federman, eds., ACP Medicine, section 12, chap. 9. New York: WebMD.

• Loblaw DA, et al. (2007). Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology, 25(12): 1596–1605.

Last updated:	July 01, 2008
Author:	Bets Davis, MFA
Reviewed By:	E. Gregory Thompson, MD - Internal Medicine, Christopher G. Wood, MD, FACS - Urology/Oncology
Editors:	Susan Van Houten, RN, BSN, MBA, Pat Truman, MATC